Cargando…

In Vivo Pharmacodynamic Study of Cefiderocol, a Novel Parenteral Siderophore Cephalosporin, in Murine Thigh and Lung Infection Models

The pharmacokinetic (PK) and pharmacodynamic (PD) parameters which correlated with the in vivo efficacy of cefiderocol were evaluated using neutropenic murine thigh and lung infection models in which the infections were caused by a variety of Gram-negative bacilli. The dose fractionation study using...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakamura, Rio, Ito-Horiyama, Tsukasa, Takemura, Miki, Toba, Shinsuke, Matsumoto, Shuhei, Ikehara, Tatsuya, Tsuji, Masakatsu, Sato, Takafumi, Yamano, Yoshinori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2019
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709502/ https://www.ncbi.nlm.nih.gov/pubmed/31262762 http://dx.doi.org/10.1128/AAC.02031-18

Ejemplares similares

In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria
por: Ito, Akinobu, et al.
Publicado: (2017)

Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa
por: Ito, Akinobu, et al.
Publicado: (2016)

256 S-649266, a Novel Siderophore Cephalosporin: Mechanisms of enhanced activity and beta-lactamase stability
por: Tsuji, Masakatsu, et al.
Publicado: (2014)

Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin
por: Katsube, Takayuki, et al.
Publicado: (2019)

In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe
por: Longshaw, Christopher, et al.
Publicado: (2020)

In Vitro Activity and In Vivo Efficacy of Cefiderocol against Stenotrophomonas maltophilia
por: Nakamura, Rio, et al.
Publicado: (2021)

Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin
por: Sato, Takafumi, et al.
Publicado: (2019)

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016
por: Hackel, Meredith A., et al.
Publicado: (2018)

Good Correlation of Cefiderocol Between In Vivo Efficacy Murine Thigh/Lung Infection Models and MIC Determined in Iron-Depleted Conditions
por: Yamano, Yoshinori, et al.
Publicado: (2017)

Intrapulmonary Pharmacokinetic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients With Pneumonia and Healthy Subjects
por: Kawaguchi, Nao, et al.
Publicado: (2022)

252 S-649266, a Novel Siderophore Cephalosporin: In vitro activity against Gram-negative bacteria
por: Tsuji, Masakatsu, et al.
Publicado: (2014)

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infection
por: Kawaguchi, Nao, et al.
Publicado: (2021)

Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae
por: Ito, Akinobu, et al.
Publicado: (2019)

Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae
por: Ito, Akinobu, et al.
Publicado: (2018)

Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens
por: Bonomo, Robert A
Publicado: (2019)

In Vivo Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Murine Urinary Tract Infection Models
por: Matsumoto, Shuhei, et al.
Publicado: (2017)

Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects
por: Katsube, Takayuki, et al.
Publicado: (2019)

679. In vitro Activity of Cefiderocol (CFDC), a Novel Siderophore Cephalosporin, Against Difficult-to-Treat-Resistant (DTR) Gram-Negative Bacterial Pathogens From the Multi-National Sentinel Surveillance Study, SIDERO-WT (2014–2017)
por: Longshaw, Christopher, et al.
Publicado: (2019)

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study)
por: Hackel, Meredith A., et al.
Publicado: (2017)

Education: The role of the first siderophore cephalosporin Fetcroja(®) (cefiderocol) in UK clinical practice: introduction
por: Hussain, Abid
Publicado: (2021)

1366. In Vitro and In Vivo Activity of Cefiderocol against Stenotrophomonas maltophilia Clinical Isolates
por: Ito, Akinobu, et al.
Publicado: (2018)

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria
por: Mushtaq, Shazad, et al.
Publicado: (2020)

Elucidating the effect of iron acquisition systems in Klebsiella pneumoniae on susceptibility to the novel siderophore-cephalosporin cefiderocol
por: Daoud, Lana, et al.
Publicado: (2022)

Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales
por: Kaye, Keith S., et al.
Publicado: (2023)

Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects
por: Saisho, Yutaka, et al.
Publicado: (2018)

Cefiderocol, a Siderophore Cephalosporin for Gram‐Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment
por: Katsube, Takayuki, et al.
Publicado: (2016)

Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety
por: Lee, Young Ran, et al.
Publicado: (2020)

In Vivo Efficacy of Humanized Exposures of Cefiderocol Compared with Cefepime (FEP) and Meropenem (MEM) against Gram-negative Bacteria in a Murine Thigh Model
por: Monogue, Marguerite, et al.
Publicado: (2017)

723. Synergistic Effect of Cefiderocol Combined With Other Antibiotics Against Cefiderocol High MIC Isolates From the Multi-National SIDERO-WT Studies
por: Yamano, Yoshinori, et al.
Publicado: (2019)

In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against Acinetobacter baumannii Strains Recovered from Clinical Samples
por: Carcione, Davide, et al.
Publicado: (2021)

Comment on ‘Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety’
por: Koren, Andrew, et al.
Publicado: (2021)

Metabolism, Excretion, and Pharmacokinetics of [(14)C]‐Cefiderocol (S‐649266), a Siderophore Cephalosporin, in Healthy Subjects Following Intravenous Administration
por: Miyazaki, Shiro, et al.
Publicado: (2019)

Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis
por: Kawaguchi, Nao, et al.
Publicado: (2018)

2388. Efficacy of Humanized Cefiderocol Exposures Over 72 Hours Against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model
por: Stainton, Sean, et al.
Publicado: (2018)

Efficacy of Humanized Cefiderocol Exposures over 72 Hours against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model
por: Stainton, Sean M., et al.
Publicado: (2019)

1351. In vitro Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, Against Enterobacteriaceae With Defined Extended-Spectrum Β-Lactamases and Carbapenemases
por: Jacobs, Michael R, et al.
Publicado: (2018)

Efficacy of Cefiderocol in Experimental Stenotrophomonas maltophilia Pneumonia in Persistently Neutropenic Rabbits
por: Petraitis, Vidmantas, et al.
Publicado: (2022)

Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics
por: Matsumoto, Shuhei, et al.
Publicado: (2017)

Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program
por: Satlin, Michael J., et al.
Publicado: (2023)

1292. Safety Profile of the Novel Siderophore Cephalosporin Cefiderocol in Randomized Phase 2 and Phase 3 Clinical Studies of Serious Gram-Negative Infections
por: Matsunaga, Yuko, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_58jgdo3265i98rm2r9kcdl79cq